 DUBLIN, April 27, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa nemvaleukin monotherapy in patients with melanoma who have been previously treated with anti-PD-L1 therapy. The study will evaluate intravenously administered IV nemvaleukin in patients with mucosal melanoma and subcutaneously administered SC nemvaleukin in patients with advanced cutaneous melanoma. 